Recap of 2013 American Heart Association Session
Just a few weeks before the 2013 American Heart Association Sessions, Shelley Wood, the managing news editor of theheart.org emailed to ask if I was up for going to the meeting. With trips to San Francisco, Denver, Athens and Amsterdam already in the books this year, I had counted 2013 as a win. I was ready to ease into Thanksgiving and conclude the bike season with a couple of cold-weather CX races. But when opportunity presents itself, ie,,,when the big strong guy in front of you attacks, it makes sense to follow.
Yes. Yes. I am in. I was excited to see my THO friends again. I was excited to write and learn.
My role at m...
Source: Dr John M - November 24, 2013 Category: Cardiology Authors: Dr John Source Type: blogs
New Anticoagulant From Daiichi Sankyo Works Well In AF Patients
Edoxaban, a direct oral factor Xa inhibitor under development by Daiichi Sankyo, is the latest in the series of new oral anticoagulants seeking to take over the troubled role of warfarin in clinical practice. The results of ENGAGE-AF-TIMI 48 were presented at the American Heart Association meeting in Dallas and published simultaneously in the New England Journal of Medicine. The results of the trial were promising, but edoxaban may have a hard time finding its footing as the fourth new oral anticoagulant to enter the market, following dabigatran (Pradaxa), Boehringer Ingelheim; rivaroxaban (Xarelto), Johnson &#...
Source: CardioBrief - November 19, 2013 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Prevention, Epidemiology & Outcomes apixaban atrial fibrillation Bristol Myers Squibb Daiichi Sankyo Direct Xa inhibitor new england journal of medicine stroke prevention Source Type: blogs
New web app: VTE guidelines
It’s been a while since I’ve coded a new medical web app but what better incentive than a colleague asking you for help – in this case, to convert a CPG to an app. The CPG in question are guidelines on the management of Venous Thromboembolism (source). It was not difficult to convert the document into an app and the tools I used were:
1) Source document in Word format
2) A Word to HTML Converter
3) NSBApp Studio
It was a matter of breaking up the document into sections and making it a menu driven system to display html content. An app is also ideal for computing scores and in this web app, there are tools...
Source: The Palmdoc Chronicles - October 21, 2013 Category: Technology Consultants Authors: palmdoc Tags: medical apps medical apps for doctors Medical Calculators Medical/PDA Software News Medwebapp Thrombosis VTE Source Type: blogs
Will The Bleeding Stop? Pradaxa Topped FDA Side Effect Reports
Will the bleeding stop? Last year, the FDA concluded that bleeding rates associated with Pradaxa, a relatively new bloodthinner, were no higher than among patients given warfarin, a decades-old medical standard. The assessment was designed to allay concerns that Pradaxa, which is used to reduce the risk of stroke and blood clots in patients with atrial fibrillation, but has been linked to hundreds of deaths.
Meanwhile, a new analysis finds that Pradaxa, which was approved two years ago by the FDA, generated the largest number of adverse events reported directly to the agency during 2012. In all, there were 683 such reports...
Source: Pharmalot - October 17, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
The LITFL Review 112
The LITFL Review is your regular and reliable source for the highest highlights, sneakiest sneak peaks and loudest shout-outs from the webbed world of emergency medicine and critical care. Each week the LITFL team casts the spotlight on the best and brightest from the blogosphere, the podcast video/audiosphere and the rest of the Web 2.0 social media jungle to find the most fantastic EM/CC FOAM (Free Open Access Meducation) around.
Welcome to the 111th edition, brought to you by:
Kane Guthrie [KG] from LITFL
Tessa Davis [TRD] from LITFL and Don’t Forget The Bubbles
Brent Thoma [BT] from BoringEM, and
Chris Nickson [C...
Source: Life in the Fast Lane - October 14, 2013 Category: Emergency Medicine Doctors Authors: Kane Guthrie Tags: Education eLearning Emergency Medicine Featured Intensive Care LITFL review LITFL R/V Source Type: blogs
When Doctors' Names are Bought and Sold
Recently, an envelope arrived for me containing an advertisement from Mercedes-Benz:
Mercedes Benz Offer (Click to enlarge)
The advertisement was co-branding with the American Medical Association, leading me to suspect the obvious: my name was sold.
Why does this bother me so? After all, the AMA advocates for physicians, don't they? Surely they need the money to do all their important (Source: Dr. Wes)
Source: Dr. Wes - September 25, 2013 Category: Cardiology Authors: Westby G. Fisher, MD Tags: rant dabigatran warfarin AMA apixaban pharmaceutical industry rivaroxaban Source Type: blogs
Disappointing Results with Dabigatran for Mechanical Valves
Despite being more durable than bioprosthetic valves, mechanical heart valves are often not chosen because of the requirement for lifelong anticoagulant therapy. It has been hoped that the newer generation of oral anticoagulants might eventually replace warfarin, making anticoagulation more tolerable and better accepted, since these agents don’t require continuous monitoring and have much fewer serious interactions with other drugs and food. So far, however, there has been no convincing demonstration that the the newer agents are as safe and effective as warfarin for this indication. RE-ALIGN was a phase 2 dose-valid...
Source: CardioBrief - September 1, 2013 Category: Cardiology Authors: Larry Husten Tags: Uncategorized Anticoagulant Artificial heart valve dabigatran European Society of Cardiology new england journal of medicine RE-ALIGN warfarin Source Type: blogs
A statistical joke called “Non-Inferiority” drug trial !
Of late many drugs are entering the market for human consumption backed up by Non -Inferiority trials (NIT ) .Few examples.
“The ONTARGET trial: Telmisartan is non-inferior to Ramipril in New Study Results Published in the New England …”
“Feb 20, 2013 – … in the New England Journal of Medicine Show Dabigatran Etexilate ... daily was non-inferior to warfarin (p=0.01) in preventing recurrent VTE, …”
What is the logic behind these Non inferiority trials ?
Why it came into vogue ?
Do you agree with the concept of NIT ?
Take Our Poll
I have taken the privilege...
Source: Dr.S.Venkatesan MD - August 27, 2013 Category: Cardiology Authors: dr s venkatesan Tags: Cardiology-Statistics Uncategorized gimmicks in medical statistics non inferiority clinical trials Non inferiority drug trials Source Type: blogs
Post-marketing experience with dabigatran
(Source: Notes from Dr. RW)
Source: Notes from Dr. RW - August 21, 2013 Category: Internists and Doctors of Medicine Tags: hematology cardiovascular Source Type: blogs
Top medicine articles for June-July 2013
Here are my suggestions for some of the top articles in medicine for June-July 2013:
Does Cigarette Smoking Make You Ugly and Old? Am. J. Epidemiol. Association of smoking and facial wrinkling may convince young persons not to begin smoking & older smokers to quit http://buff.ly/16g6NJe
"I COUGH" mnemonic: Reducing Postoperative Pulmonary Complications http://buff.ly/1e7ln6J
Perioperative beta blockers linked to lower 30-day mortality in patients with 2 or more Revised Cardiac Risk Index http://buff.ly/14PlJQq
"Trimethylamine-N-oxide (TMAO) is the new enemy within. We make it in our bowels" http://buff.ly/ZiM7KA
...
Source: Clinical Cases and Images - Blog - July 31, 2013 Category: Professors and Educators Tags: Health News of the Day Source Type: blogs
The COURAGE patients who crossed over; two new analyses link dabigatran to MI risk; beta-blockers in HF get bum rap for most "side effects"; 10 emerging uses for cardiac CT
(Source: Blogs@theHeart.org)
Source: Blogs@theHeart.org - July 19, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: blogs
